Veozah Alternatives: Which Option Fits Your Reason for Leaving?

The HRT Index Editorial TeamIndependent women's health research

Last reviewed:August 31, 2026

Editorial research — not medically reviewed by a clinician. Why this label

Last updated: August 31, 2026 · Last verified: August 31, 2026 · By The HRT Index Editorial Team. Educational research, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

Before you replace a prescription

Use your reason for leaving Veozah, liver results, medication list, coverage, and state to build a safer starting conversation before you switch.

Find the right menopause care path

The best Veozah alternatives are Lynkuet if you want another FDA-approved nonhormonal neurokinin drug with fewer scheduled liver checks; paroxetine mesylate 7.5 mg if you want a lower-cost FDA-approved nonhormonal pill and do not take tamoxifen; and FDA-approved hormone therapy if you are a candidate and want the most effective treatment for hot flashes.

Best for: women leaving Veozah because of cost, coverage, side effects, monitoring burden, a drug interaction, inadequate relief, or access.

Not for you if: you have symptoms of possible liver injury right now, need an abnormal liver result interpreted, or are trying to switch prescriptions without a prescriber.

Your deciding issue	The first category to discuss	The fact that changes the answer
Cost or denied coverage	Generic venlafaxine, gabapentin, oxybutynin, an SSRI, or FDA-approved hormone therapy if appropriate	Example generic fills in our August 31 price basket were about $8.50 to $53.37; Veozah and Lynkuet were roughly $474 and $613 cash
Fewer scheduled liver checks	Lynkuet or a category without a hot-flash-specific liver schedule	Veozah schedules six liver panels in year one; Lynkuet schedules two
Another FDA-approved nonhormonal pill	Lynkuet or paroxetine mesylate 7.5 mg	Paroxetine is a poor fit with tamoxifen; Lynkuet has its own liver, interaction, pregnancy, drowsiness, and seizure warnings
Strongest treatment when hormones are appropriate	FDA-approved systemic hormone therapy	Hormone therapy remains the most effective treatment for vasomotor symptoms
Every prescription door feels closed	Menopause-focused CBT or clinical hypnosis	Both are recommended at Level I by The Menopause Society; that does not mean equal efficacy to a drug

That last column is the whole page. So let’s get specific, fast.

Stop reading and get care now if you have possible liver-injury symptoms

If you are taking Veozah and develop new tiredness, loss of appetite, nausea, vomiting, itching, yellow skin or eyes, pale stools, dark urine, or abdominal pain, the current prescribing information says to stop Veozah immediately and seek medical attention, including liver blood tests.^[1] Do not wait for your next scheduled panel, and do not finish this article first.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

Start here: why are you leaving Veozah?

This page routes six different exit problems: cost or coverage, liver monitoring or an abnormal result, inadequate relief, side effects, a contraindication, and local access. Those are not six versions of the same question. Each one changes which alternatives remain open and what needs to happen before your next prescription.

Every other page on this topic can hand you an inventory. That is the wrong tool when something just took your current option away. You already know other medicines exist. What you need to know is which doors are still open to you.

Your reason for leaving	What it actually changes	Go straight to
Too expensive, or my plan denied it	Brand-price options stay impractical unless coverage or assistance changes; generic categories move up	The cost door
The liver warning, the lab burden, or a bad result	Monitoring burden and the reason for the abnormal result become the decision	The liver door
It gave me too little relief	This is an efficacy and mechanism question, not automatically a safety question	The “didn’t work” door
The side effects are the problem	The exact side effect matters more than the drug name	The nine-option matrix
A contraindication or interaction ruled me out	Cirrhosis, kidney function, baseline liver values, and drug interactions carry over differently	The blocked-door cross-map
My pharmacy cannot get it	Local stocking is not the same as an FDA-listed national shortage	The availability door

You do not have to read every section. Find your row and take the shortest path.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

Not sure which door is yours?
Find My HRT Path asks about your symptoms, age and uterus status, route preference, risk history, insurance situation, and state. In about 90 seconds, it gives you a personal care-path shortlist and flags when an in-person clinician is the better starting point. Free. No signup.
Find My HRT Path →

What are the best Veozah alternatives in 2026?

Nine evidence-backed categories belong in a serious Veozah alternatives comparison: Lynkuet, paroxetine mesylate 7.5 mg, SNRIs, other SSRIs, gabapentin, oxybutynin, FDA-approved hormone therapy, menopause-focused cognitive behavioral therapy, and clinical hypnosis. Their regulatory status, monitoring burden, price, interactions, and practical fit are not interchangeable.

Two definitions before the table:

FDA-approved for hot flashes means the FDA reviewed that specific product for that specific indication. Off-label means a drug is FDA-approved for another use and prescribed for hot flashes based on evidence and clinical judgment. Off-label prescribing is legal and common, but it is not the same regulatory status. We do not blur the two.

The nine-option Veozah exit matrix

Option	What it is	FDA-approved for menopausal hot flashes?	The Menopause Society 2023 status	August 31 price example	Scheduled liver panels in year one	Best-fit discussion	Main reasons to pause
Lynkuet (elinzanetant)	Dual NK1/NK3 receptor antagonist; two 60 mg capsules at bedtime	Yes — approved October 24, 2025^[4]	Approved after the 2023 statement	$613.25 for 60 capsules at SingleCare’s listed coupon price	2	You want to remain nonhormonal, fewer scheduled panels matter, and sleep disturbance is part of the problem	Pregnancy is contraindicated; baseline liver threshold; CYP3A4/grapefruit interactions; daytime impairment; seizure warning^[3]
Paroxetine mesylate 7.5 mg	Low-dose SSRI capsule, formerly branded Brisdelle	Yes	SSRI/SNRI class: Recommended, Level I	$52.12 for 30 capsules at GoodRx’s listed price	No hot-flash-specific schedule in labeling	You want an FDA-approved nonhormonal generic and tamoxifen is not part of your regimen	The label says to consider avoiding it with tamoxifen; pregnancy is contraindicated; the SSRI boxed warning, adverse effects, and interactions still apply^[5]
Venlafaxine or desvenlafaxine	SNRIs used off-label	No	Recommended, Level I	$15.73 for venlafaxine IR 37.5 mg, 30 tablets, in our basket	No hot-flash-specific schedule	A clinician wants an SNRI option; venlafaxine is often considered when tamoxifen is involved	Formulation and dose matter; antidepressant warnings and discontinuation symptoms mean it generally should not be stopped abruptly
Escitalopram or citalopram	SSRIs used off-label	No	Recommended, Level I	$11.47 for escitalopram 10 mg, 30 tablets; $9.00 for citalopram 20 mg, 30 tablets	No hot-flash-specific schedule	An SSRI is clinically appropriate and the medication list clears	Antidepressant warnings, adverse effects, cardiac considerations, and interactions are product- and patient-specific
Gabapentin	Seizure/nerve-pain medicine used off-label	No	Recommended, Level I	$11.35 for 300 mg, 60 capsules	No hot-flash-specific schedule	Night symptoms dominate and a clinician believes the sedating profile may be useful	Drowsiness, dizziness, falls, and kidney-based dose adjustment
Oxybutynin ER	Bladder antimuscarinic used off-label	No	Recommended, Levels I–II	$8.50 for 10 mg, 30 tablets	No hot-flash-specific schedule	Hot flashes and overactive-bladder symptoms overlap	Dry mouth, constipation, urinary retention, reduced heat tolerance, and anticholinergic burden
FDA-approved systemic hormone therapy	Estrogen; endometrial protection is generally needed when systemic estrogen is used by someone with a uterus	Yes, by product	Most effective treatment for vasomotor symptoms^[7]	$53.37 example basket: estradiol patch 0.05 mg/day, 8 patches, plus progesterone 100 mg, 30 capsules	No hot-flash-specific liver-panel schedule in the comparison labels	You are a candidate and want the most effective treatment	Product-specific contraindications and history review; unexplained bleeding needs evaluation; route and uterus status matter
Menopause-focused CBT	Structured cognitive behavioral therapy for the impact and management of symptoms	Not applicable	Recommended, Level I	Therapist/program cost varies	0	You want a non-drug path or medication choices are narrow	Access, cost, time, and finding a menopause-specific protocol
Clinical hypnosis	A structured clinical protocol delivered by a qualified practitioner	Not applicable	Recommended, Level I	Practitioner cost varies	0	You want a non-drug path with Level I support	Qualified practitioners can be hard to find; it is not the same as a generic relaxation app

Prices are reproducible examples for the strength and quantity shown, not treatment recommendations or promises about your receipt. Coupon prices vary by pharmacy, ZIP code, date, formulation, and quantity. The price ledger below links every source.

Two options we deliberately did not promote

Clonidine. It appears on many competing lists, but The Menopause Society’s 2023 nonhormone statement puts clonidine in the not recommended group. We are not padding the list to look thorough.^[6]

Black cohosh, soy, and supplement stacks. The same statement places supplements and herbal remedies, soy foods and extracts, and the soy metabolite equol in its not-recommended group for treating vasomotor symptoms.^[6] That is an evidence judgment about hot-flash treatment—not a claim that every lifestyle measure is useless.

One more thing that is not a substitute

Low-dose vaginal estrogen is not a replacement for a systemic hot-flash treatment. It is used for genitourinary symptoms such as vaginal dryness, burning, painful sex, and some urinary symptoms. If those are your main problem and hot flashes are not, you are in the wrong comparison—and catching that before a paid consult matters.

Does the thing that blocked Veozah block every alternative?

No. Veozah’s label contraindicates known cirrhosis, severe renal impairment or end-stage renal disease, and concomitant CYP1A2 inhibitors; it also says not to start when ALT, AST, or total bilirubin is at least twice the upper limit of normal. Those barriers do not transfer equally to Lynkuet, antidepressants, gabapentin, oxybutynin, hormone therapy, CBT, or hypnosis.^[1]

This is the most useful question on the page because it turns “Veozah is off the table” into a smaller, solvable problem. We built the cross-map by checking the exact Veozah barrier against the current Lynkuet and Brisdelle labels and the practical constraints of the other categories.

The blocked-door cross-map

What stopped Veozah	Lynkuet	Paroxetine 7.5 mg	Venlafaxine / escitalopram	Gabapentin	Oxybutynin	Systemic hormone therapy	CBT / hypnosis
Known cirrhosis	Not a clean workaround: Lynkuet is not recommended in moderate or severe hepatic impairment	Product-specific clinician review; hepatic impairment can affect dosing	Product-specific clinician review; hepatic impairment can affect dosing	Primarily renally eliminated, but sedation and overall condition still matter	Product-specific review	Many systemic estrogen labels list liver dysfunction or disease as a contraindication; the exact product matters	No medication-related liver restriction
eGFR 15–29	The Lynkuet label does not use Veozah’s same severe-renal-impairment contraindication, but the prescriber still reviews renal status	Product-specific review	Product-specific review	Dose must be adjusted to kidney function	Limited data/caution	Not primarily selected by kidney function alone; product and history review still apply	No medication-related kidney restriction
End-stage renal disease or dialysis	Not recommended; the label says it has not been studied in ESRD with or without dialysis	Product-specific review	Product-specific review	Kidney-based dosing and specialist review	Limited data/caution	Product and history review	No medication-related kidney restriction
A CYP1A2 inhibitor	The specific CYP1A2 prohibition does not automatically carry over, but Lynkuet has a different CYP3A4/grapefruit interaction screen	The medication still needs its own interaction review	The medication still needs its own interaction review	Separate interaction and sedation review	Separate interaction review	Separate interaction review	No drug-enzyme interaction
Baseline ALT, AST, or bilirubin ≥2× ULN	Also blocked at initiation under the current label	No matching hot-flash-specific initiation threshold	No matching hot-flash-specific initiation threshold	No matching hot-flash-specific initiation threshold	No matching hot-flash-specific initiation threshold	No matching hot-flash-specific threshold, but liver disease and the cause of the result still require review	No medication-related threshold
Tamoxifen	OASIS-4 studied elinzanetant during endocrine therapy, but this remains an oncology-team decision	The label says to consider avoiding concomitant use	Venlafaxine is commonly discussed as an alternative, but oncology still owns the choice	May be considered after oncology review	May be considered after oncology review	Usually not the starting path after hormone-receptor-positive breast cancer; oncology decides	Fully available as an adjunct or non-drug path

Three findings change the next move:

1. The CYP1A2 door can reopen—but not without a new interaction check. Veozah contraindicates weak, moderate, and strong CYP1A2 inhibitors. In the label study, the strong CYP1A2 inhibitor fluvoxamine increased fezolinetant exposure by about 840%.^[1] That specific prohibition is not a Lynkuet contraindication. Lynkuet instead brings CYP3A4 restrictions, dose changes with moderate inhibitors, and a grapefruit warning.^[3]

2. The baseline liver door closes twice. Both labels say not to initiate when ALT or AST, or total bilirubin, is at least twice the upper limit of normal.^[1]^[3] If a baseline result stopped Veozah, Lynkuet is not the loophole. The next question is why the value was high.

3. When several medication doors close, the strongest remaining evidence may not be a pill. Menopause-focused CBT and clinical hypnosis are both Level I recommendations in the same 2023 statement that gives Level I status to fezolinetant.^[6] That is not proof of equal efficacy. It is proof that “nothing is left” is often wrong.

If cost is why you are leaving: what does the Veozah savings cap actually do?

Veozah’s savings program advertises $0 for the first eligible commercial-insurance fill and as little as $30 for later fills, but assistance is capped at $4,000 per calendar year. Under a 12-fill January-to-December model, the cap lasts all year only when the same pre-card patient responsibility is about $360.83 or less per fill.^[8]

Let’s start with the moment. You had been paying $30. You went to collect a refill and the number was suddenly three digits. Your prescription may not have changed. Your plan may not have changed. The annual assistance bucket may simply have run low.

What the current Veozah terms say

Eligible patients must have commercial prescription insurance.
The advertised patient cost is $0 for the first fill and as little as $30 for later monthly fills.
The maximum program benefit is $4,000 per calendar year.
Medicare, Medicaid, Medigap, TRICARE, VA, DoD, and state pharmaceutical-assistance coverage are excluded.
When Astellas determines that a commercially insured claim was not approved, the program may limit help to $1,250 across two fills, except where prohibited.
Eligibility is not based on income.^[8]

Every one of those terms is public. None of them is obvious from a pharmacy receipt.

The corrected $361 model

The useful number is not Veozah’s list price or what your insurance plan paid. It is C: your pre-card patient responsibility after an approved commercial-insurance claim for each equal monthly fill.

If the advertised structure works exactly—and C is above $30, where cap exhaustion can matter—the card’s annual contribution is:

Annual assistance = C + 11(C − 30) = 12C − 330

Set annual assistance to the $4,000 ceiling:

12C − 330 = 4,000
C = $360.83

The $361 line
If 12 equal fills fall inside one calendar year, and your pre-card responsibility is about $360.83 or less each time, the published $4,000 maximum can support the advertised $0-first-fill/$30-thereafter structure for all 12 fills. Above that line, assistance can become partial before it disappears.

The return to full price is not always immediate. The last assisted fill can be partial.

Equal pre-card responsibility, C	Advertised $30 price lasts through	First partial-benefit fill	First completely unassisted fill
$350	Fill 12	None in the 12-fill model	None in the 12-fill model
$400	Fill 10	Fill 11: up to $270 assistance, leaving about $130	Fill 12: about $400
$500	Fill 8	Fill 9: up to $210 assistance, leaving about $290	Fill 10: about $500
$584	Fill 7	Fill 8: up to $92 assistance, leaving about $492	Fill 9: about $584
Commercial claim not approved	Separate route	Program terms may cap help at $1,250 across two fills	Depends on the claim and remaining benefit

This is The HRT Index’s arithmetic from Astellas’ published terms, not a number Astellas publishes. It assumes 12 equal fills in one calendar year, exact $0/$30 pricing, no plan change, and no other program restriction. Starting later in the year changes the result because the $4,000 maximum resets by calendar year. Confirm the live terms and your remaining benefit before relying on the model.

Two more things can move the number:

Copay accumulators and maximizers. Some plans do not credit manufacturer help toward your deductible or out-of-pocket maximum. Ask your plan directly how manufacturer assistance is handled.

A denial is not a coupon problem. A formulary exclusion, prior-authorization requirement, or step-therapy rule needs a coverage response. A savings card cannot make an unapproved claim approved.

How Veozah and Lynkuet access differs by coverage

Commercial insurance opens the advertised copay paths; government coverage does not. Uninsured or underinsured patients need the manufacturers’ separate assistance routes, which have different eligibility rules. For Medicare Part D, the relevant protection is the 2026 $2,100 out-of-pocket cap for covered Part D drugs—not a manufacturer copay card.^[9]^[10]

Coverage	Veozah	Lynkuet	The lever that actually applies
Commercial / employer plan	Eligible patients may pay $0 first fill and as little as $30 later, subject to the $4,000 calendar-year maximum and other terms	Eligible commercially insured patients may pay as little as $25 per month through BlinkRx; we did not find a public annual maximum	Formulary status, prior authorization, step therapy, and the live program maximum
Medicare, Medicaid, TRICARE, VA, other government coverage	Copay card excluded	Commercial copay offer does not apply	Formulary, prior authorization, Medicare’s 2026 $2,100 Part D cap for covered drugs, Extra Help when eligible, or a lower-cost alternative
Uninsured or underinsured	Astellas Support Solutions has a separate patient-assistance pathway for eligible patients	Bayer has separate patient-assistance resources	Apply to the assistance program; do not assume copay-card eligibility
Cash pay without assistance	About $474.11 in our live 30-tablet coupon check	About $613.25 in our live 60-capsule coupon check	Compare generic categories, FDA-approved hormone therapy if appropriate, and the total cost of visits plus medication

If you are on Medicare, the advertised $30 is not your path. Your actual questions are whether the drug is on your plan’s formulary, what utilization rules apply, whether Extra Help changes your cost, and whether a generic category would solve the same symptom problem at a fraction of the price.

The part that costs us money to tell you

Here is the damaging admission, and it is not a small one.

Several of the lowest-cost evidence-backed prescriptions on this page earn The HRT Index nothing. Our August 31 basket found oxybutynin ER at about $8.50, gabapentin at $11.35, venlafaxine at $15.73, and an example estradiol-patch-plus-progesterone basket at $53.37. You can fill those at an ordinary pharmacy with no affiliate referral.

We are telling you anyway because a page that hides the generic door is not a decision resource. The prescription may be cheap. The bottleneck is often getting a clinician who will review the reason you are leaving, check the interaction or contraindication, handle any required coverage work, and own the follow-up.

Does that sound like your situation?
Midi Health serves all 50 states, works with many PPO plans, and publishes self-pay rates of $250 for the initial visit and $150 for follow-ups. Midi’s materials include hormonal and nonhormonal menopause treatment, but a visit never guarantees Veozah, an alternative prescription, or plan approval.
Check Midi coverage and availability → (affiliate link)
Where Midi does not fit: it cannot treat Medicaid or Medi-Cal members, even as self-pay patients. Medicare beneficiaries may use self-pay care, but Midi is not covered by Medicare and cannot submit Medicare claims. Ask before booking whether the clinician will submit a prior authorization or appeal for the medication at issue; do not assume that service from the insurance model alone.
If flat pricing matters more than insurance billing, compare the provider models in the online-care section below before paying.

What is the cheapest Veozah alternative that actually works?

The lowest-priced prescription examples in our August 31, 2026 basket were oxybutynin ER at $8.50, citalopram at $9, gabapentin at $11.35, and venlafaxine at $15.73. Those drugs are used off-label. The FDA-approved nonhormonal generic paroxetine mesylate 7.5 mg was $52.12, while Veozah and Lynkuet remained brand-price drugs.

This table is deliberately narrow. Each row names the dosage form, strength, quantity, source, and verification date so you can reproduce the comparison. It does not imply that the example dose is right for you.

Reproducible August 31, 2026 price basket

Product and exact basket	Status for hot flashes	Lowest live price we recorded	Source	What the number leaves out
Veozah 45 mg, 30 tablets	FDA-approved	$474.11	SingleCare	Visits, six scheduled year-one liver panels, insurance rules
Lynkuet 60 mg, 60 capsules	FDA-approved; 30 days at the labeled two-capsule dose	$613.25	SingleCare	Visits, two scheduled liver panels, insurance rules
Paroxetine mesylate 7.5 mg, 30 capsules	FDA-approved	$52.12	GoodRx	Visits and interaction review
Venlafaxine immediate-release 37.5 mg, 30 tablets	Off-label	$15.73	GoodRx	Formulation and prescribed dose can change quantity and price
Escitalopram 10 mg, 30 tablets	Off-label	$11.47	GoodRx	Visits and interaction review
Citalopram 20 mg, 30 tablets	Off-label	$9.00	GoodRx	Visits, dose, and product-specific safety review
Gabapentin 300 mg, 60 capsules	Off-label	$11.35	GoodRx	Dose frequency, kidney function, sedation burden
Oxybutynin ER 10 mg, 30 tablets	Off-label	$8.50	GoodRx	Anticholinergic adverse effects and clinical fit
Estradiol patch 0.05 mg/day, twice weekly, 8 patches	FDA-approved hormone therapy	$33.82	GoodRx	Whether this product/route is appropriate; visit cost
Progesterone 100 mg, 30 capsules	FDA-approved progestogen	$19.55	GoodRx	Whether endometrial protection is needed and what regimen is prescribed
Example patch + progesterone basket	Two FDA-approved components	$53.37	Sum of the two rows above	Not a treatment recommendation; dose and regimen are clinician-specific

Coupon prices can change without notice and vary by pharmacy and ZIP code. Recheck the exact strength and quantity before the prescription is sent. “Retail price,” “cash price,” and “coupon price” are not interchangeable.

The $52 detail that prevents a confusing pharmacy conversation

There are two paroxetine products people collapse into one name.

Paroxetine mesylate 7.5 mg is the capsule FDA-approved specifically for moderate-to-severe vasomotor symptoms associated with menopause. It was sold as Brisdelle, and an approved generic exists.^[5]

Paroxetine hydrochloride is used at other strengths for psychiatric indications and may be prescribed off-label for hot flashes. It is a different salt, dose range, and regulatory status.

If the FDA-approved hot-flash product is the one under discussion, the words to write down are paroxetine mesylate 7.5 mg.

Cheap does not mean low-burden

A low tablet price can hide a bad practical fit. Gabapentin can cause dizziness and next-day sedation. Oxybutynin brings anticholinergic effects such as dry mouth, constipation, urinary retention, and reduced heat tolerance. SSRIs and SNRIs bring their own interaction and discontinuation issues.

Your usable cost is:

Medication + visits + required labs + follow-up + time burden − assistance you actually qualify for

That is the number to compare—not the smallest coupon in a search result.

If the liver warning is why you are leaving: how many tests does each option require?

Veozah carries an FDA boxed warning for rare but serious liver injury and schedules six liver panels in year one: baseline, months 1, 2, 3, 6, and 9. Lynkuet schedules baseline testing and one repeat at month 3. The other categories on this page do not carry a hot-flash-specific scheduled liver-panel sequence in their labeling.^[1]^[2]^[3]

The year-one liver-testing ledger

Option	Hot-flash-specific scheduled liver panels in year one	Label schedule	What can still trigger other testing
Veozah	6	Baseline; months 1, 2, 3, 6, and 9	Symptoms or abnormal values can require immediate testing and discontinuation
Lynkuet	2	Baseline; month 3	Symptoms, liver history, or abnormal values
Paroxetine mesylate 7.5 mg	No fixed liver-panel schedule for this indication	None in the VMS label	Medical history, other medicines, clinician judgment
Venlafaxine / escitalopram / citalopram	No fixed VMS liver-panel schedule	None	Product-specific monitoring and clinical history
Gabapentin	No fixed VMS liver-panel schedule	None	Kidney function informs dosing
Oxybutynin	No fixed VMS liver-panel schedule	None	Clinical history and adverse effects
FDA-approved hormone therapy	No single class-wide VMS liver-panel schedule	Product-specific	History, bleeding evaluation, and product-specific monitoring
CBT / clinical hypnosis	0 medication panels	Not applicable	None for the intervention itself

Veozah schedules four more year-one panels than Lynkuet. If blood draws, lab copays, travel, or time off work are part of why you want out, that is not a trivial preference. It is treatment burden.

The burden is transferred, not erased

Now the part we would be wrong to hide:

A lighter lab schedule is not proof that Lynkuet is safer. Veozah entered the market in 2023. The FDA added its boxed warning in December 2024 after postmarketing reports of serious liver injury.^[2] Lynkuet entered the U.S. market in October 2025. Fewer scheduled tests and a shorter real-world track record can both be true.

Lynkuet also carries burdens Veozah does not:

two capsules at bedtime;
pregnancy contraindication;
CYP3A4 and grapefruit restrictions;
a warning about somnolence and daytime impairment;
nervous-system adverse reactions—including sleepiness, fatigue, dizziness, vertigo, and presyncope—reported in 11.9% of treated women versus 3.5% on placebo;
a current seizure warning.^[3]

You are not escaping burden. You are deciding which burden is acceptable.

The August 2026 Lynkuet label change most pages have not caught

The current Lynkuet prescribing information, revised August 2026, says postmarketing cases of seizure have been reported. The label also describes one seizure during clinical trials in a patient with a prior seizure history.^[3]

Postmarketing reports cannot establish incidence or prove causation on their own. They still belong in the decision because the warning is now part of the current FDA labeling. A seizure history, medicines that lower seizure threshold, and work that depends on alertness all belong in the consult.

Any summary built from the original October 2025 label is now incomplete unless it includes the August 2026 seizure language.

If an abnormal result is what stopped you
The next step is not choosing a drug from a table. It is finding out why the value was high. Find My HRT Path can flag when an in-person clinician is the right starting point before you pay for an online visit that can only refer you out.
Check whether online care fits this situation →

Is Lynkuet actually better than Veozah?

No randomized head-to-head trial has compared Lynkuet with Veozah. The closest published comparison used statistical matching across separate trials and found comparable average reductions in hot-flash frequency and severity, with greater sleep-disturbance improvement for elinzanetant and no significant difference in overall menopause-related quality of life. That is useful—not definitive.^[11]

This is the question everyone wants answered, so it deserves the clean answer: nobody has run the race.

You cannot put an improvement percentage from one company’s trial beside a percentage from the other company’s trial and declare a winner. The trials enrolled different women, started with different symptom burdens, and were run under different conditions. Lynkuet’s own label warns that adverse-reaction rates across different clinical programs cannot be directly compared.^[3]

What the closest indirect comparison found

Evidence	Method	What it can support	What it cannot support
Stute et al., Maturitas; online 2025, 2026 issue	Matching-adjusted indirect comparison using patient-level fezolinetant SKYLIGHT-1 and -2 data matched to published elinzanetant OASIS-1 and -2 populations	Similar average VMS frequency/severity effects; sleep disturbance improved with both and more with elinzanetant; no significant overall menopause-related quality-of-life difference	Individual response, definitive superiority, real-world safety ranking, or the importance of price and monitoring to you
Randomized head-to-head trial	None exists	Nothing	Any claim that one drug has proved itself superior to the other
2025 Obstetrics & Gynecology meta-analysis	Pooled separate placebo-controlled trials	Not used in this page’s conclusion	The journal issued an Expression of Concern in 2026, so presenting its result as settled evidence would be irresponsible^[12]

The authorship matters. The matching analysis used Astellas patient-level data, and the author list includes Astellas employees; Astellas makes Veozah.^[11] That does not invalidate the analysis. It means the funding and data source belong beside the conclusion rather than hidden in a bibliography.

The decision still comes down to things the indirect comparison does not answer:

six scheduled liver panels versus two;
one tablet versus two bedtime capsules;
boxed warning versus shorter postmarket history;
CYP1A2 restrictions versus CYP3A4/grapefruit restrictions;
daytime impairment and seizure warnings;
your insurance and assistance eligibility.

That is why “better” is the wrong final question. The useful question is which trade-off solves the reason you are leaving without opening a worse problem.

Which Veozah alternative is best for night sweats and sleep?

When nighttime symptoms dominate, Lynkuet and gabapentin deserve a different conversation from daytime-only hot flashes. Elinzanetant showed a stronger sleep-disturbance signal than fezolinetant in the matching analysis, while gabapentin is often used when night symptoms are prominent. Both can create next-day drowsiness, dizziness, or impaired function—the trade-off that decides the fit.^[3]^[11]

Here is the tension nobody should flatten:

The category with the clearest sleep signal can also make the next morning harder.

Lynkuet is taken at bedtime. Its label warns about somnolence and daytime impairment and tells patients not to drive or perform hazardous activities until they know how it affects them.^[3] Gabapentin has a similar practical shape: bedtime use may align with nighttime symptoms, while grogginess, dizziness, and balance problems can make it a bad fit for someone who drives early, operates equipment, gets up with a child, or already falls.

So the real question is not “which one helps sleep?” It is:

Which sleep-versus-next-day trade-off can I live with on an ordinary Tuesday?

A woman driving to a job site at 6 a.m. and a woman working from home do not have the same answer.

One more thing to rule out: night waking is not always vasomotor. Sleep apnea, anxiety, alcohol timing, room temperature, pain, and other medicines can also wake you. If the sweats improved but the waking did not, tell the clinician. That changes the problem.

Track this for seven days before the visit

Time of each hot flash or night sweat
Severity and duration
How long you stayed awake afterward
Room temperature and bedding changes
Alcohol and caffeine timing
Medication time
Next-day sleepiness, driving, falls, or near-falls

Seven days of timestamps beats “my sleep is terrible” in a 20-minute consult.

What if Veozah did not work well enough?

Veozah’s label does not create a mandatory 12-week stop rule. Its pivotal trials measured outcomes at weeks 4 and 12, but the decision to continue, stop, or switch depends on benefit, adverse effects, adherence, liver results, and your prescriber’s plan. A weak response to Veozah does not predict failure of every other mechanism.^[1]

Do not turn the 12-week trial endpoint into a label rule. If you have a possible liver-injury symptom, the label says stop immediately and seek care. If you do not, the useful move is to define what “did not work” means before changing categories.

Was there no change, or not enough change? Frequency, severity, nighttime waking, and ability to function can move differently.

Was the trial continuous? Coverage gaps, missed doses, and a late refill can make an apparent efficacy failure hard to interpret.

Did anything else change? A new medicine, supplement, alcohol pattern, illness, or sleep problem can blur the answer.

Was there a partial response? A partial response is still data. Whether it is worth keeping, adjusting, or replacing is a prescriber decision.

Different mechanisms give you different odds. Veozah selectively blocks NK3 receptors. Lynkuet blocks NK1 and NK3. SSRIs, SNRIs, gabapentin, oxybutynin, and hormone therapy work through different pathways. “Veozah did not do enough” is information about one treatment—not a verdict on the field.

Bring this to the efficacy conversation

start date and every interruption;
dose and time taken;
baseline and current flash count;
changes in severity and night waking;
adverse effects with dates;
all medicines and supplements;
liver-panel dates and actual values;
coverage status and any denial letter;
the one outcome that would make treatment worth continuing.

That is the appointment that goes somewhere.

Can you take hormone therapy instead of Veozah?

Often, yes—when a clinician determines systemic hormone therapy fits your history. It remains the most effective treatment for menopausal vasomotor symptoms. On February 12, 2026, the FDA approved boxed-warning changes for six named menopausal hormone products, not the entire class, so the exact product and its current label still matter.^[7]^[14]

What changed in February 2026

The FDA’s current page lists six products with updated prescribing information:^[14]

Prometrium — progestogen alone
Divigel, Cenestin, and Enjuvia — systemic estrogen alone
Estring — topical vaginal estrogen
Bijuva — systemic estrogen plus progestogen

For those products, the FDA approved removal of boxed-warning statements about cardiovascular disease, breast cancer, and probable dementia. The agency said 29 companies had submitted proposed changes. It did not request removal of the endometrial-cancer boxed warning from systemic estrogen-alone products.^[15]

We rechecked the FDA’s live product list on August 31, 2026. It still names those six products.

That is narrower than “the hormone therapy boxed warning is gone.” The specific generic patch or pill at your pharmacy may carry a different current label. Estring is also a local vaginal product; its label update does not turn it into a hot-flash treatment.

If an old warning ended the hormone conversation years ago, the FDA’s position has materially changed. Reopening the conversation is reasonable. Reopening it is not the same as self-declaring eligibility.

Who needs a closer product-specific review?

Systemic hormone therapy is not a checkbox you clear from a blog. The prescribing information and clinical history commonly require close review when there is:

unexplained vaginal bleeding;
liver dysfunction or disease;
prior estrogen-sensitive cancer;
prior heart attack, stroke, or blood clot;
known clotting risk;
another product-specific contraindication.

A family history is not the same as a personal history. “Needs specialist review” is not automatically “never.” The product, route, age, time since menopause, uterus status, symptoms, and history all change the calculation.

If you have a uterus, systemic estrogen generally needs an endometrial-protection plan, commonly a progestogen. That is part of the regimen, not an optional add-on.

Route matters. Oral, transdermal, spray, and local products are not interchangeable. The best route is a clinical decision as well as a preference.

If this reopened a door you thought was closed
Use Find My HRT Path to separate insurance-billed care, cash-pay prescribing, state availability, and situations that need an in-person clinician. Then compare the exact provider model before paying.
Get your HRT care-path shortlist →

What if you take tamoxifen or cannot take estrogen?

“Nonhormonal” narrows the field but does not make every remaining option appropriate. The Brisdelle label says to consider avoiding paroxetine with tamoxifen because CYP2D6 inhibition can reduce tamoxifen’s activity. Elinzanetant was studied during endocrine therapy in OASIS-4, but its liver, interaction, pregnancy, drowsiness, and seizure rules still apply.^[5]^[13]

This section prepares an oncology conversation. It does not replace one.

The paroxetine and tamoxifen problem, plainly

Tamoxifen must be converted to active metabolites, and CYP2D6 helps perform that conversion. Paroxetine strongly inhibits CYP2D6. The Brisdelle label states that concomitant use can reduce tamoxifen’s effectiveness and says to consider avoiding the combination.^[5]

That does not make venlafaxine or any other drug automatically right. It explains why venlafaxine is often discussed when an antidepressant-class treatment is needed and tamoxifen is in the picture.

Lynkuet is not automatically “the cancer-safe one”

OASIS-4 randomized women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone-receptor-positive breast cancer and found elinzanetant reduced symptom frequency versus placebo.^[13] That is directly relevant evidence.

It does not erase these questions:

Are your baseline liver results below the label threshold?
Do you have a seizure history?
Does your medication list create a CYP3A4 problem?
Can you tolerate possible daytime impairment?
Is pregnancy possible?
Who will coordinate this with oncology?

The U.S. indication is for moderate-to-severe vasomotor symptoms due to menopause. Do not turn one relevant trial into an unsupervised “cancer-safe” stamp.

Two distinctions that should not be flattened

A family history of breast cancer is not a personal history of breast cancer.

Being at elevated risk is not the same as receiving endocrine therapy after a hormone-receptor-positive cancer.

Those paths can lead to different options, and the oncology team should own the decision when active or prior cancer treatment is involved.

Questions to bring to oncology

Which options are compatible with my cancer history and current endocrine therapy?
Does my medication list create a CYP2D6 or CYP3A4 problem?
Who owns follow-up—oncology, gynecology, primary care, or a menopause specialist?
Which labs do I need, and who reviews them?
Which symptoms should trigger an urgent call?
Could this option affect adherence to my cancer treatment?
Can menopause-focused CBT or clinical hypnosis be added?

There is no provider button here on purpose. If you are managing cancer treatment, the next step is the team already responsible for that treatment. We are not routing around them for a commission.

Do natural alternatives to Veozah work?

The Menopause Society’s 2023 statement does not recommend supplements, herbal remedies, soy foods, soy extracts, or equol for treating vasomotor symptoms. The non-drug approaches it recommends at Level I are menopause-focused cognitive behavioral therapy and clinical hypnosis. “Same evidence level” does not mean they were proved equal to fezolinetant.^[6]

What the 2023 statement actually recommends

Recommended	Evidence level in the statement	What that means on this page
Cognitive behavioral therapy	I	Evidence-backed non-drug option
Clinical hypnosis	I	Evidence-backed non-drug option
SSRIs and SNRIs	I	Prescription classes; most use is off-label except paroxetine mesylate 7.5 mg
Gabapentin	I	Off-label prescription
Fezolinetant	I	FDA-approved prescription
Oxybutynin	I–II	Off-label prescription
Weight loss	II–III	May help in applicable patients; not a direct drug substitute
Stellate ganglion block	II–III	Procedure with specialized access and risk review

The not-recommended column is broader than supplements: it also includes clonidine, paced respiration, soy and equol, acupuncture, cannabinoids, and several lifestyle or alternative interventions for treating vasomotor symptoms. That does not mean every item lacks other health or comfort value; it means the panel did not recommend it as a VMS treatment.

Not recommended	Evidence level in the statement
Paced respiration	I
Supplements and herbal remedies	I–II
Cooling techniques, avoiding triggers, exercise, yoga, mindfulness-based intervention, relaxation, suvorexant, soy foods and soy extracts, equol, cannabinoids, acupuncture, and calibration of neural oscillations	II
Chiropractic interventions and clonidine	I–III
Dietary modification and pregabalin	III

Level I means good and consistent scientific evidence; Level II means limited or inconsistent evidence; Level III means consensus and expert opinion in this statement.^[6]

What “not recommended” does—and does not—mean

This is a judgment about evidence for treating vasomotor symptoms. It is not a claim that exercise is bad for you or that a fan cannot make a hot flash more tolerable.

Cooling clothes, bedding changes, and identifying triggers may improve comfort. They should not be sold as treatment equivalents.

Supplements deserve extra caution because product composition varies and interactions are possible. “Natural” is not a regulatory status or safety guarantee. The HRT Index does not run supplement affiliate links on this page.

The good news buried in the list

CBT and clinical hypnosis sit in the recommended column at Level I. That does not mean “as effective as Veozah.” It means the same panel found good and consistent evidence for each intervention within its own evidence base.

If medicines are off the table, ask for a menopause-focused CBT protocol or a clinician trained in the specific hypnosis protocol—not a generic wellness app sold as the same thing.

How do you switch off Veozah?

Veozah’s label does not give a taper schedule. A switch plan depends on why you are stopping, whether symptoms may return before the next option works, the new drug’s interaction and initiation rules, and your current liver results. Do not invent an overlap or washout schedule from a listicle; line up the prescriber and replacement first when it is safe to do so.^[1]

If possible, avoid creating an unplanned gap. Symptoms can return after an effective treatment stops, but the timing and severity differ. The exception is the liver-warning situation: possible liver-injury symptoms require immediate discontinuation and medical attention under the label.

The switch conversation, in eight items

Current Veozah dose and the time you take it
Start date, missed stretches, and intended last-dose date
Baseline and current symptom record
Every prescription, over-the-counter medicine, and supplement
Liver-test dates and actual values
Your reason for leaving in one sentence
Insurance denial, formulary notice, or savings-benefit information
Cancer treatment, seizure history, kidney function, driving or hazardous work, and whether pregnancy is possible

A universal switch schedule would be irresponsible. Paroxetine and venlafaxine have discontinuation considerations. Lynkuet has a baseline liver threshold and interaction screen. Hormone therapy requires product- and history-specific review.

What to do with leftover tablets

Do not save them as a private restart plan after an abnormal result. Ask the pharmacy about a take-back option or follow the FDA’s medicine-disposal instructions for the product. If a warning symptom made you stop, call rather than waiting to see whether it passes.

What if your pharmacy cannot get Veozah?

We found no current Veozah entry in the FDA Drug Shortages database in our August 31, 2026 check. That does not prove every pharmacy can obtain it. A local out-of-stock message, wholesaler delay, plan-mandated specialty pharmacy, and an FDA-listed national shortage are different problems with different solutions.^[17]

Before abandoning a medicine that works:

Ask whether the pharmacy can special-order it and when the wholesaler expects delivery.
Ask whether your insurer requires a specific mail-order or specialty pharmacy.
Call another chain location and an independent pharmacy.
Confirm that the rejected claim is about stock—not prior authorization, refill timing, or a high patient responsibility.
Ask the prescriber whether the prescription can be transferred or re-sent.

A pharmacy shelf can change. Your label contraindications do not. Find out which problem you actually have before switching categories.

Where can you get a Veozah alternative evaluated online?

Online care helps only when the clinician can evaluate the category you need, serve your state, handle your insurance or cash-pay model, arrange required labs, and refer out when telehealth is the wrong setting. We verified four provider models from first-party pages; one—Winona—has a material FDA-status contradiction that must be resolved before treating it as an FDA-approved-only route.

We evaluate providers under The HRT Index Verification Standard using five pillars, in this order: clinical legitimacy, care quality, medication fit, price transparency, access. We do not publish numeric provider scores.

Provider-stated versus verified access table

Provider	Provider-stated model and pricing	What we verified August 31, 2026	Where it does not fit	Decision-resolution next step
Midi Health	Insurance-billed virtual menopause care; $250 initial and $150 follow-up self-pay	Serves all 50 states; works with many PPO plans; hormonal and nonhormonal care. Medicare beneficiaries can use self-pay but Midi is not covered by Medicare. Medicaid/Medi-Cal members cannot be treated even self-pay	No Medicaid/Medi-Cal; insurance cost is not knowable before adjudication; no prescription or approval guarantee	Check Midi coverage and availability → (affiliate)
Hers	Cash-pay menopause plans; provider page publishes oral treatment from $79/month and patch-based treatment from $134/month on a 12-month plan	Offers clinician-prescribed oral or transdermal estradiol and progesterone when appropriate; cash pricing is published; service availability varies by state	Does not bill insurance; 12-month pricing structure; current terms require cancellation at least two days before renewal	See Hers menopause availability and current pricing → (affiliate)
Sesame Care	Dedicated menopause subscription advertised from $59/month; medication cost separate	30-minute telehealth start, ongoing support, prescriptions sent to a local pharmacy, and basic labs included when ordered through the program; cancellation should be submitted at least 48 hours before renewal	This is a subscription service, not a one-off no-membership visit. Controlled-medication availability can vary; Sesame lists gabapentin but also restricts controlled substances, so confirm state-specific prescribing before paying	Check Sesame menopause care in your state → (affiliate)
Winona	Cash-pay messaging and mail-order model for ages 35–59; provider pages publish $54 estrogen tablets, $149 patches, and $39 progesterone capsules	Serves 37 states plus Puerto Rico; no insurance; future subscriptions can be canceled, while a newly processed order has a 24-hour cancellation/refund window	First-party conflict: product pages call certain tablets, patches, and capsules FDA-approved, while a Help Center article says “Winona’s treatments are not FDA approved” and describes compounding. Body creams are compounded and are not FDA-approved. Do not use Winona as an FDA-approved-only route until the exact manufacturer, product, and NDC are confirmed	Compare Winona against the verified provider field →

The Winona contradiction is not a wording problem. It changes whether a reader seeking an FDA-approved alternative can rely on the route. Until Winona reconciles its own statements, the safest editorial treatment is to disclose the conflict and require product-level confirmation before payment. We do not present compounded preparations as equivalent to FDA-approved products.

What to confirm before you pay

Can the clinician evaluate the actual reason I am leaving Veozah?
Do they prescribe the category I am considering?
What exact product, manufacturer, and—when relevant—NDC would be dispensed?
Is it FDA-approved for this use, FDA-approved for another use and prescribed off-label, or compounded?
Where are liver tests ordered, what do they cost, and who reviews abnormal results?
Is medication included or separate?
Will the practice submit a prior authorization or appeal? Get the answer in writing.
What happens if the clinician decides the requested treatment is not appropriate?
How often are follow-ups and what do they cost?
Can they coordinate with oncology or another treating clinician?
What are the renewal, refill, and cancellation deadlines?

If a service cannot answer those before you pay, that is your answer.

Still unsure which provider model fits?
Use Find My HRT Path to filter by symptoms, insurance, state, route preference, uterus status, and safety flags before you open four checkout pages.
Build your care-path shortlist →

What did we verify, and what remains yours to confirm?

We checked current FDA labels, manufacturer savings terms, CMS rules, peer-reviewed evidence, provider first-party pages, and live coupon listings on August 31, 2026. We did not verify your formulary, your checkout total, a pharmacy’s inventory, or what a clinician will prescribe. Those answers exist only at the plan, pharmacy, intake, or consult level.

Confirmed from current primary sources

Veozah’s boxed warning, liver schedule, initiation threshold, contraindications, and CYP1A2 interaction data from the February 2026 prescribing information.^[1]
The FDA’s December 2024 safety communication explaining the boxed-warning change.^[2]
Lynkuet’s baseline-plus-month-3 liver schedule, 11.9% nervous-system adverse-reaction rate, pregnancy contraindication, CYP3A4/grapefruit restrictions, renal and hepatic limitations, and August 2026 seizure language.^[3]
Brisdelle’s FDA indication and tamoxifen/CYP2D6 warning.^[5]
The Menopause Society’s recommended and not-recommended categories and evidence levels.^[6]
The six products on the FDA’s updated menopausal-hormone-therapy list as of August 31, 2026.^[14]
Veozah’s $4,000 calendar-year maximum and denied-claim clause.^[8]
Lynkuet’s commercially insured “as little as $25” BlinkRx route; no public annual copay-assistance maximum was found.^[9]
Medicare’s 2026 $2,100 Part D out-of-pocket cap for covered Part D drugs.^[10]
Each exact coupon basket and provider fact dated in the tables above.

Confirm during intake, checkout, or the pharmacy call

Whether your plan covers the drug and what utilization rules apply
Whether a prior authorization or appeal will be submitted
Your remaining manufacturer-assistance balance
The live price at your ZIP code and pharmacy
Whether the pharmacy can obtain the product today
The exact product, manufacturer, and NDC a telehealth service will dispense
State availability at the moment you book
Which labs the clinician will order and what they cost
Whether a new interaction, diagnosis, or label change alters the plan

How we work: The HRT Index Verification Standard means we read every published price, separate FDA-approved from compounded options, verify state availability and insurance, and re-check on a fixed schedule—top providers monthly, the full roster quarterly. We apply the five pillars in this order: clinical legitimacy, care quality, medication fit, price transparency, access. We do not publish invented per-provider scores.

This page was produced by the editorial team and was not medically reviewed by a clinician. It helps you decide what to verify and what to ask. It does not diagnose, prescribe, interpret a lab result, or tell you to start, stop, combine, or taper medication.

Found something wrong? Report a correction. We date material corrections.

What do women actually say about leaving or staying on Veozah?

Public reviews show the decision friction this page addresses: cost changes, inadequate relief, early adverse effects, and dramatic relief in other users. They are anecdotes, not clinical evidence. We use them to preserve the searcher’s language and show why one average trial result cannot tell an individual woman what will happen.^[18]

WebMD’s Veozah page showed 43 reviews and a 4.0/5 average when checked August 31, 2026. That aggregate is not a treatment recommendation, and the site’s reviewer details are self-reported.^[18]

On giving it a real chance and leaving anyway. A reviewer posting as Kitkat on July 5, 2025 said she had taken Veozah for three months, was still having flashes, and had developed insomnia and gastrointestinal symptoms. Her phrase—“giving it a chance to work but it hasn’t”—captures the reader in the inadequate-relief section.^[18]

On early uncertainty during endocrine therapy. A reviewer posting as AMW on October 20, 2025 described worse flushing and sweating early in treatment, with back pain that had eased by day nine, and asked whether relief came later for other users.^[18]

On it working fast. A reviewer posting as Loving life now on June 14, 2025 described sleeping through the first night without sweats or flashes after months of disrupted sleep.^[18]

Positive and negative accounts belong together. Veozah works well for many women. This page is for the woman whose cost, safety screen, side effects, access, or response changed the calculation. That is not a verdict on the drug.

Frequently asked questions

Is there a generic for Veozah?

No FDA-approved generic fezolinetant was found in our August 31, 2026 Orange Book check. Veozah remains the U.S. brand product. Recheck the FDA Orange Book before each scheduled update because generic status can change.^[16]

Is Lynkuet safer than Veozah?

That has not been proved. Lynkuet has no boxed warning and schedules two liver panels in year one versus Veozah’s six, but it has a shorter U.S. postmarket history and its own warnings for daytime impairment, pregnancy, interactions, liver thresholds, and seizure risk. Fewer scheduled tests do not prove greater safety.^[1]^[3]

What is the cheapest prescription alternative to Veozah?

In our exact August 31 basket, oxybutynin ER was $8.50, citalopram $9, gabapentin $11.35, and venlafaxine $15.73. Those are off-label options. Paroxetine mesylate 7.5 mg, the FDA-approved nonhormonal generic, was $52.12. Clinical fit matters more than the coupon winner.

Why did my Veozah price suddenly increase?

One possible reason is the $4,000 calendar-year savings maximum. In a 12-equal-fill model with the advertised $0 first fill and $30 thereafter, the full-year threshold is about $360.83 of pre-card patient responsibility per fill. Above it, the final assisted fill can be partial before the benefit disappears. Start month, claim approval, and plan design can change the result.^[8]

Does Medicare cover Veozah or Lynkuet?

Coverage depends on the individual Part D formulary and any prior-authorization or step-therapy rules. Manufacturer commercial copay offers do not apply to Medicare. For covered Part D drugs, the 2026 annual out-of-pocket cap is $2,100; Extra Help may reduce costs further for eligible people.^[10]

What is the difference between Brisdelle and regular paroxetine?

Brisdelle is paroxetine mesylate 7.5 mg, FDA-approved for moderate-to-severe menopausal vasomotor symptoms. “Regular paroxetine” usually refers to paroxetine hydrochloride at other strengths for psychiatric indications; it may be used off-label for hot flashes but is not the same salt, dose, or approval.^[5]

Which alternative is strongest for night sweats and sleep?

The closest indirect comparison found a stronger average sleep-disturbance improvement with elinzanetant than fezolinetant. Gabapentin is also often discussed when night symptoms dominate. Both can impair next-day function, so driving, work, falls, and morning responsibilities can decide the fit.^[3]^[11]

Can I take hormone therapy after breast cancer?

Systemic hormone therapy after breast cancer is an oncology decision and is generally not the routine starting path for hormone-receptor-positive disease. A family history is not a personal history. Nonhormonal prescriptions and evidence-backed non-drug options are usually the first categories discussed with the oncology team.

Do I need liver tests with the alternatives?

Lynkuet’s label schedules baseline testing and a repeat at month 3. The other categories on this page do not carry a fixed hot-flash-specific liver-panel schedule in their labeling, although a clinician may order testing for your history, another medicine, or an abnormal result.^[3]

Does black cohosh work for hot flashes?

The Menopause Society’s 2023 statement places supplements and herbal remedies in its not-recommended category for vasomotor symptoms. The non-drug approaches it recommends at Level I are menopause-focused CBT and clinical hypnosis.^[6]

Will hot flashes return after I stop Veozah?

They may. If Veozah was suppressing symptoms, those symptoms can return after discontinuation, but timing and severity vary. The label does not provide a taper schedule. Arrange the next clinical step before the last dose when it is safe to do so; liver-warning symptoms are the exception and require immediate action.^[1]

Can I switch directly from Veozah to Lynkuet?

Only a prescriber with your current liver results and medication list can set the sequence. Both labels say not to initiate when ALT, AST, or total bilirubin is at least twice the upper limit of normal, and Lynkuet adds CYP3A4, grapefruit, pregnancy, daytime-impairment, and seizure considerations.^[1]^[3]

Still not sure which HRT program is right for you?

You came here because something took Veozah off the table—or made you wonder whether it should.

Now you know that the field is nine categories wide, the exact Veozah blocker does not transfer equally, the $361 line needs calendar-year and partial-benefit assumptions, fewer liver panels do not prove a safer drug, and some of the strongest evidence-backed alternatives are generic or non-drug options that pay us nothing.

If you know your door, take the relevant section and your checklist to the clinician.

If you are stuck between care models, Find My HRT Path turns the constraints on this page into a personal shortlist in about 90 seconds. No account. No email.

Use Find My HRT Path →

Keep reading

Nonhormonal options for menopause — the wider evidence-backed treatment field
FDA-approved HRT medication list — product and route options kept separate from compounded care
HRT cost in 2026 — medication, visit, lab, insurance, and membership costs
Compare online HRT providers — provider models, current prices, and access limits

Sources

FDA labels and regulatory sources

¹ VEOZAH (fezolinetant) prescribing information, DailyMed; revised February 2026

² FDA drug safety communication: rare serious liver injury and boxed warning for Veozah

³ LYNKUET (elinzanetant) prescribing information, DailyMed; revised August 2026

⁴ FDA Drug Trials Snapshot: Lynkuet; approval October 24, 2025

⁵ BRISDELLE (paroxetine mesylate) prescribing information, DailyMed

¹⁴ FDA: Menopausal Hormone Therapies with Updated Prescribing Information

¹⁵ FDA press announcement: labeling changes to menopausal hormone therapy products, February 12, 2026

¹⁶ FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

¹⁷ FDA Drug Shortages database

Clinical guidance and peer-reviewed evidence

⁶ The Menopause Society. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573–590.

⁷ The Menopause Society. Hormone Therapy patient and professional education.

¹¹ Stute P, Shapiro CM, Morga A, et al. Fezolinetant compared with elinzanetant for the treatment of vasomotor symptoms associated with menopause: a matching-adjusted indirect comparison. Maturitas. Online 2025; 2026 issue.

¹² Expression of Concern: Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms. Obstetrics & Gynecology. 2026.

¹³ Cardoso F, Parke S, Brennan DJ, et al. Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer. New England Journal of Medicine. 2025.

Pricing, savings, and Medicare

⁸ VEOZAH Savings Program terms and support

⁹ LYNKUET savings and support

¹⁰ Medicare: costs in the coverage gap and the 2026 $2,100 out-of-pocket cap

Coupon-price sources are linked in the dated price table. Prices were checked August 31, 2026.

Provider first-party sources

Midi Health: pricing and insurance, Medicare, and Medicaid/Medi-Cal policy
Hers: menopause treatment and published pricing, terms
Sesame: menopause treatment, terms
Winona: FAQ and availability, product pages for its estrogen tablets, estradiol patch, and progesterone capsules, plus its conflicting Help Center FDA-status statement

Consumer experience

¹⁸ WebMD: Veozah patient reviews. Used only for attributed voice-of-customer examples, not efficacy or safety evidence.

The HRT Index publishes independent editorial research for education and pre-consult decision-making. This page is not medical advice, diagnosis, or treatment, and it was not medically reviewed by a clinician. FDA-approved and compounded medications are labeled separately; compounded products are not FDA-approved and are not presented as equivalent to FDA-approved medication. Find My HRT Path is handled under our consumer health data privacy policy.

Last verified: August 31, 2026 · Affiliate disclosure · Report a correction

Match the alternative to the problem you are solving.

Read the broader nonhormonal menopause options guide, compare Veozah and Lynkuet, review the Veozah liver-monitoring requirements, or use Find My HRT Path before changing a prescribed regimen.

Keep reading: